References
- Anker P, Mulcahy H, Chen X Q, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999; 18: 65–73
- Leon S A, Shapiro B, Sklaroff D M, Yaros M J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977; 37: 646–650
- Han H S, Escalon M P, Hsiao B, Serafini A, Lossos I S. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol 2009; 20: 309–318
- Gallagher A, Armstrong A A, MacKenzie J, Shield L, Khan G, Lake A, et al. Detection of Epstein–Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Int J Cancer 1999; 84: 442–448
- Gandhi M K, Lambley E, Burrows J, Dua U, Elliott S, Shaw P J, et al. Plasma Epstein–Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 460–464
- Au W Y, Pang A, Choy C, Chim C S, Kwong Y L. Quantification of circulating Epstein–Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004; 104: 243–249
- Kim W S, Kim H S, Kim K H, Kim K H, Chang M H, Ji S H, et al. Whole blood Epstein–Barr Virus (EBV) DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma, in press
- Gandhi M K. Epstein–Barr virus-associated lymphomas. Expert Rev Anti Infect Ther 2006; 4: 77–89
- Lee J, Park Y H, Kim W S, Lee S S, Ryoo B Y, Yang S H, et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 2005; 41: 1402–1408
- Stevens S J, Pronk I, Middeldorp J M. Toward standardization of Epstein–Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol 2001; 39: 1211–1216
- Yang J, Tao Q, Flinn I W, Murray P G, Post L E, Ma H, et al. Characterization of Epstein–Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000; 96: 4055–4063
- Preiksaitis J K, Pang X L, Fox J D, Fenton J M, Caliendo A M, Miller G G. Interlaboratory comparison of Epstein–Barr virus viral load assays. Am J Transplant 2009; 9: 269–279
- Park S, Lee J, Ko Y H, Han A, Jun H J, Lee S C, et al. The impact of Epstein–Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007; 110: 972–978
- Keegan T H, Glaser S L, Clarke C A, Gulley M L, Craig F E, Digiuseppe J A, et al. Epstein–Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol 2005; 23: 7604–7613
- Dupuis J, Emile J F, Mounier N, Gisselbrecht C, Martin-Garcia N, Petrella T, et al. Prognostic significance of Epstein–Barr virus in nodal peripheral T-cell lymphoma, unspecified: a groupe d'Etude des lymphomes de l'adulte (GELA) study. Blood 2006; 108: 4163–4169